Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pyrotinib + trastuzumab + docetaxel + carboplatin versus trastuzumab + docetaxel + carboplatin as neoadjuvant therapy for locally advanced HER2-positive breast cancer
ChiCTR1900026200Phase 3Not yet recruiting
- Sponsor
- First Hospital of China Medical University
- Start
- Oct 2019
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of pyrotinib, trastuzumab, docetaxel and carboplatin in breast cancer (2 arms), sponsored by First Hospital of China Medical University. Primary endpoint: Total pathologic complete response rate. Planned start Oct 2019; status: not yet recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900026200.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900026200.